A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Dose limiting toxicity (DLT)
研究概览
简要总结
To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial carcinoma
详细描述
This trial is designed to first include 6 subjects to confirm the dose safety. If the toxicity is intolerable, the dose of chemotherapeutic drugs will be reduced depending on the toxicity for further exploration.If it was tolerated, the recommended dose was determined, and the dose was extended. 14 patients were enrolled to further observe the safety and efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old;
- •Pathologically confirmed urothelial carcinoma;
- •Terminal patients who have not received treatment or for the first time recurrence more than 6 months after the end of adjuvant chemotherapy after surgery;
- •Evaluable lesions based on RECIST V1.1;
- •ECOG score 0-1;
- •Estimated life expectancy >3 months;
- •The function of important organs meets the following requirements;
- •The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.
排除标准
- •Previously received drugs targeting PD-1, PD-L1, PD-L2 or other treatments targeting T cell costimulation or checkpoint channels;
- •Received systemic corticosteroid immunosuppressants 2 weeks before the study;
- •Suffer from active meningeal metastasis or uncontrolled, untreated brain metastasis;
- •Severe cardiovascular disease, such as New York Heart Association (New York Heart Association,NYHA standard) Grade 3-4 heart failure, unstable angina pectoris, unstable arrhythmia, or color heart photo indicates LVEF (left ventricular ejection fraction) < 50%;
- •Previous hypersensitivity to monoclonal antibodies;
- •The patient has known, active or suspected autoimmune diseases. The following conditions are allowed: skin diseases that do not require systemic treatment (such as vitiligo, psoriasis), type I diabetes, autoimmune hypothyroidism with hormone replacement therapy;
- •The study drug suffered from other active malignant tumors within 5 years before the first use of the drug. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., can be included in the group;
- •Active hepatitis B or C (unless HBV-DNA titer < 500IU/mL or copy number < 1000copies/ml, HCV-RNA negative after antiviral treatment can be included in), HIV positive or known history of acquired immunodeficiency syndrome;
- •Severe infection existed before screening, including but not limited to, infections requiring hospitalization, bacteremia, severe pneumonia, etc;
- •There has been active pulmonary tuberculosis in the past year, whether treated or not;
- •Live attenuated vaccine was used within 28 days prior to screening;
- •Patients who have previously received allogeneic bone marrow transplantation or solid organ transplantation;
- •Have received any other experimental drug treatment within 28 days prior to signing ICF;
- •Pregnant or lactating women;
- •Patients of childbearing age who refuse to use effective contraception;
- •Other researchers believe that it is not suitable to join the group.
研究组 & 干预措施
Combined treatment group
All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
干预措施: anti-PD-L1 antibody (Drug)
Combined treatment group
All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
干预措施: albumin bound paclitaxel (Drug)
结局指标
主要结局
Dose limiting toxicity (DLT)
时间窗: 21 days after first dose
Adverse events of level 3 or above related to the study drug occurring within 21 days after the first dose as assessed by CTCAE v5.0.
Recommended phase II dose (RP2D)
时间窗: 21 days after first dose
DLT occurs in no more than 1/6 subjects, this dose is defined as RP2D.
次要结局
- PD-L1 expression(12 months)
- TMB expression(12 months)
- objective response rate(12 months)
- progression free survival(12 months)